Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|81|3-4|251-258

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.3-4, 2011-11, pp. : 251-258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical significance of half‐lives of tumor markers α‐fetoprotein and des‐γ‐carboxy prothrombin after hepatectomy for hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E183-E193

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

Favorable α‐fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 3, 2010-03 ,pp. : 605-612

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-08 ,pp. : 298-303

Karger

Access to resources Recommend Favorite

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 261-266

Karger

Access to resources Recommend Favorite